Resources from the same session
55O - IMADGIST: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
Presenter: Axel Le Cesne
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
56O - A phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828): Safety and efficacy in patients with dedifferentiated liposarcoma
Presenter: Peter Reichardt
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant abstracts 55O and 56O
Presenter: Cesar Serrano
Session: Proffered Paper session 2
Resources:
Slides
Webcast
40O - Diagnostic trajectories of rare cancer patients in the Netherlands: Results from a nationwide cross-sectional survey
Presenter: Olga Husson
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
146O - Measuring health-related quality of life in solid rare cancer patients according to EURACAN domains: A progress report of an EORTC Quality of Life group (QLG) study
Presenter: Catarina Simoes Padilla
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
51O - The European Prospective Investigation into Cancer and nutrition cohort (EPIC): A gateway to rare cancer epidemiological research – Insights from the EPIC Rare Cancers Working Group
Presenter: Matthieu Foll
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant abstracts 40O, 146O and 51O
Presenter: Joanna Szkandera
Session: Proffered Paper session 2
Resources:
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session 2
Resources:
Webcast